Martin Shkreli, the controversial former hedge fund manager known as “Pharma Bro,” questioned but ultimately defended Palantir Technologies Inc.’s growth projections on Wednesday, calling analysis of the company’s $4 million average revenue per customer “flawed.”
Palantir’s $4 Million ARPC Estimate ‘Flawed,’ Says ‘Pharma Bro’ Martin Shkreli, But ‘I Wouldn’t Bet Against Them’
